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Abstract
Background: Burkholderia pseudomallei is intrinsically resistant to aminoglycosides and macrolides, mostly due to AmrAB-
OprA efflux pump expression. We investigated the molecular mechanisms of aminoglycoside susceptibility exhibited by
Thai strains 708a, 2188a, and 3799a.
Methodology/Principal Findings: qRT-PCR revealed absence of amrB transcripts in 708a and greatly reduced levels in 2188a
and 3799a. Serial passage on increasing gentamicin concentrations yielded 2188a and 3799a mutants that became
simultaneously resistant to other aminoglycosides and macrolides, whereas such mutants could not be obtained with 708a.
Transcript analysis showed that the resistance of the 2188a and 3799a mutants was due to upregulation of amrAB-oprA
expression by unknown mechanism(s). Use of a PCR walking strategy revealed that the amrAB-oprA operon was missing in
708a and that this loss was associated with deletion of more than 70 kb of genetic material. Rescue of the amrAB-oprB region
from a 708a fosmid library and sequencing showed the presence of a large chromosome 1 deletion (131 kb and 141 kb
compared to strains K96243 and 1710b, respectively). This deletion not only removed the amrAB-oprA operon, but also the
entire gene clusters for malleobactin and cobalamin synthesis. Other genes deleted included the anaerobic arginine deiminase
pathway, putative type 1 fimbriae and secreted chitinase. Whole genome sequencing and PCR analysis confirmed absence of
these genes from 708a. Despitemissing several putative virulence genes, 708a was fully virulent in a murinemelioidosis model.
Conclusions/Significance: Strain 708a may be a natural candidate for genetic manipulation experiments that use Select
Agent compliant antibiotics for selection and validates the use of laboratory-constructed D(amrAB-oprA) mutants in such
experiments.
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Introduction
Melioidosis is a disease caused by Burkholderia pseudomallei [1,2].
Melioidosis is endemic to tropical and subtropical regions of the
world [3] and is considered an emerging disease (e.g. NE Thailand
[4]) as well as a disease of biodefense importance [4]. Melioidosis
has received worldwide popular attention in the wake of the 2004
SE Asia Tsunami disaster [5,6,7,8]. Treatment of melioidosis is
complicated by the intrinsic resistance of B. pseudomallei to many
antibiotics, including aminoglycosides, macrolides, several penicil-
lins, and first and second generation cephalosporins [1,2,9]. Factors
complicating drug therapy are the ability of B. pseudomallei to form
biofilms [10] and to enter into prolonged, presumably intracellular,
latency periods of up to six decades in a human host [11].
Genome sequence analysis has provided an indication of
possible mechanisms of resistance to antimicrobial compounds,
but less than a handful of resistance genes have been experimen-
tally confirmed to date [12]. The K96243 and other B. pseudomallei
genomes encode an arsenal of efflux pumps, including 10 pumps
belonging to the resistance nodulation cell division (RND) family,
which play major roles in clinically significant antibiotic resistance
in Gram-negative bacteria. Two of these, AmrAB-OprA [13] and
BpeAB-OprB [14] were reported to play major roles in high-level
resistance to aminoglycosides and macrolides, but our unpublished
results with strain 1026b indicate that BpeAB-OprB does not
efflux aminoglycosides. Using a surrogate Pseudomonas aeruginosa
strain we recently showed that BpeEF-OprC extrudes chloram-
phenicol and trimethoprim [15]. While the majority of clinical B.
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pseudomallei isolates exhibit high levels of aminoglycoside and
macrolide resistance, rare (,1:1000) isolates are susceptible to
these antibiotics. It has been noted that the resistance profile of
these isolates matches that of amrAB-oprA mutants suggesting
possible involvement of AmrAB-OprA in intrinsic aminoglycoside
and macrolide resistance or lack thereof [16], but this has not yet
been experimentally demonstrated. In this report we provide
evidence that the susceptibility of three isolates from NE Thailand
is indeed due to lack of, or greatly reduced, AmrAB-OprA
expression, either due to deletion or as to as yet unknown
mechanisms. Furthermore, deletion of an ,131 kb region of
chromosome 1 in one strain not only removed amrAB-OprA, but
also genes encoding several putative virulence factors and other
functions implicated in bacterial pathogenesis and physiology.
Materials and Methods
Bacterial strains, media and growth conditions
B. pseudomallei strains used in this study are listed in Table 1.
Escherichia coli strains used for cloning experiments were DH5a
[17] or DH5a(lpir) (laboratory strain). All bacteria were routinely
grown with aeration at 37uC. Low salt (5 g/L NaCl) Lennox LB
broth (LSLB) and agar (MO BIO Laboratories, Carlsbad, CA)
were used as rich media. M9 medium [18] with 10 mM glucose
was used as the minimal medium. Unless otherwise noted,
antibiotics were added at the following concentrations: 100 mg/
ml ampicillin (Ap), 12.5 mg/ml chloramphenicol (Cm), 15 mg/ml
gentamicin (Gm), 35 mg/ml kanamycin (Km) and 25 mg/ml
zeocin (Zeo) for E. coli; 1,000 mg/ml Km and 2,000 mg/ml Zeo
for wild-type B. pseudomallei and 50 mg/ml for Gm susceptible B.
pseudomallei strains. Antibiotics were either purchased from
Sigma, St. Louis, MO (ampicillin, chloramphenicol, erythromy-
cin, kanamycin, polymyxin B and streptomycin), EMD Biosci-
ences, San Diego, CA (gentamicin), Invitrogen, Carlsbad, CA
(zeocin) or Biomol via VWR International, West Chester, PA
(spectinomycin).
DNA and genetic methods
Published procedures were employed for manipulation of DNA,
and transformation of E. coli and B. pseudomallei [19,20,21]. Plasmid
DNAs were isolated from E. coli and B. pseudomallei using the
QIAprep Mini-spin kit (Qiagen, Valencia, CA). Colony PCR with
B. pseudomallei was performed as previously described [20]. B.
pseudomallei chromosomal DNA was isolated using the Gentra
Puregene DNA purification kit (Qiagen). Custom oligonucleotides
were synthesized by Integrated DNA Technologies (Coralville,
IA). Isolation of chromosomally-integrated mini-Tn7 elements
followed by Flp-mediated selection marker excision was performed
using recently published procedures [20]. Quantitative real-time
PCR was performed using the methods and primer sets described
by Kumar et al. [22]. Other primer sequences are shown in
Table 1. Total RNA was extracted from cells grown to late log
phase (optical density at 600 nm ,0.7) in LSLB medium without
antibiotics using the RNeasy Mini Kit (Qiagen).
Mutant construction
For isolation of D(amrR-amrAB-oprA) mutants, three partially
overlapping DNA fragments representing flanking DNA segments
and the Kmr marker were PCR-amplified from 50 ng pPS1927 and
pFKM2 [20] DNA templates and then spliced together by an
overlap extension PCR. To do this, the following fragments were
amplified in a first-round PCR using Platinum Taq HiFi DNA
polymerase (Invitrogen, Carlsbad, CA) and the following primers: a
892-bp amrR upstream fragment using primers 1581 (59- agggtgtc-
cacatccttgaa) and 1582 (59- TCAGAGCGCTTTTGAAGCTAA-
TTCGggacacttcaacggcaagat), a 828-bp oprA downstream fragment
using primers 1583 (59- AGGAACTTCAAGATCCCCAATTCG-
gtcgccgaatacgagaagac) and 1584 (59- gaaatacgccttgacgcact), and a
1382-bp FRT-nptII-FRT fragment using primers 596 (59-CGAAT-
TAGCTTCAAAAGCGCTCTGA) and 597 (59-CGAATTGGG-
GATCTTGAAGTTCCT)(Lowercase letters denote chromosome-
specific sequences and uppercase letters FRT cassette-specific
sequences.) These fragments were combined in a second PCR
and, after gel purification, the resulting recombinant,3.1-kb DNA
fragment was cloned into pGEM-T Easy (Novagen), which yielded
pPS2282. The D(amrR-amrAB-oprA::FRT-nptII-FRT) cassette was
excised from pPS2282 with EcoRI, blunted ended with T4 DNA
polymerase (NEB) and ligated into the SmaI site of pEX-S12pheS (C.
Lopez and H. Schweizer, unpublished) yielding pPS2354. Gene
replacement using PheS-mediated counter-selection on M9-glucose
supplemented with 0.15% p-chlorophenylalanine was performed as
previously described [23] except that E. coli strains SM10(lpir) or
RHO1 (a Km susceptible derivative of SM10[lpir] [24]; D. Rholl
and H. Schweizer, unpublished) were used for conjugation
experiments. The recipient strain was either Bp24 or Bp35 and
merodiploids were selected on LSLB medium supplemented with
1000 mg/ml Km (to select for the D[amrR-amrAB-oprA::FRT-nptII-
FRT] cassette cloned in pEX-S12pheS) and 100 mg/ml polymyxin B
(to counterselect against RHO1). p-chlorophenylalanine resistant
colonies were then obtained and screened for the presence of the
correct deletion alleles by colony PCR [20] and primers 597 and
1546 for D(amrR-amrAB-oprA)::FRT-nptII-FRT. An unmarked
D(amrR-amrAB-oprA) mutation was obtained after Flp recombinase-
mediated excision of the nptII marker using pFlpe2 [20]. The
presence of the deletion allele was verified by phenotypic (Gm
susceptibility) and genotypic (PCR with primers 1581 and 1584)
analyses.
Fosmid library construction and screening
Genomic DNA was extracted from strain 708a using the
QiAmpDNA Mini Kit (Qiagen, Valencia, CA). Fosmids contain-
Author Summary
Burkholderia pseudomallei is the etiologic agent of
melioidosis, an emerging tropical disease. Because of low
infectious dose, broad-host-range infectivity, intrinsic
antibiotic resistance and historic precedent as a biowea-
pon, B. pseudomallei was listed in the United States as a
Select Agent and Priority Pathogen of biodefense concern
by the US Centers for Disease Control and Prevention and
the National Institute of Allergy and Infectious Diseases.
The mechanisms governing antibiotic resistance and/or
susceptibility and virulence in this bacterium are not well
understood. Most clinical and environmental B. pseudo-
mallei isolates are highly resistant to aminoglycosides, but
susceptible variants do exist. The results of our studies
with three such variants from Thailand reveal that lack of
expression or deletion of an efflux pump is responsible for
this susceptibility. The large deletion present in one strain
not only removes an efflux pump but also several putative
virulence genes, including an entire siderophore gene
cluster. Despite this deletion, the strain is fully virulent in
an acute mouse melioidosis model. In summary, our
findings shed light on mechanisms of antibiotic resistance
and pathogenesis. They also validate the previously
advocated use of laboratory-constructed, aminoglycoside
susceptible efflux pump mutants in genetic manipulation
experiments.
B. pseudomallei Aminoglycoside Susceptibility
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Table 1. Strains, plasmids and primers used in this study.
Strain or Plasmid Relevant Propertiesa Reference or Source
B. pseudomallei
1026b AG and ML resistant wild-type strain; clinical isolate [45]
DD503 AG and ML susceptible D(amrR-amrAB-oprA)1026b derivative [13]
708a AG and ML susceptible clinical isolate [16]
2188a AG and ML susceptible clinical isolate [16]
3799a AG and ML susceptible clinical isolate [16]
Bp24 Spontaneous AG and ML resistant derivative of 3799a This study
Bp35 Spontaneous AG and ML resistant derivative of 2188a This study
Bp50 1026b with D(amrR-amrAB-oprA) [20]
Bp66 Low level Gmr derivative of 708a This study
Bp187 Bp24 with D(amrR-amrRAB-oprA) This study
Bp202 Bp187::mini-Tn7T-LAC This study
Bp194 Bp187::mini-Tn7T-LAC-amrA+B+-oprA+ This study
Bp192 Bp35 with D(amrR-amrAB-oprA) This study
Bp201 Bp192::mini-Tn7T-LAC This study
Bp200 Bp192::mini-Tn7T-LAC-amrA+B+-oprA+ This study
Plasmids
pEX-S12pheS Gmr; gene replacement vector Lopez and Schweizer, unpublished
pUC18T-mini-Tn7T-LAC Apr, Gmr; mini-Tn7 cloning and delivery vector [46]
pPS2142 Apr, Gmr; pUC18T-miniTn7T-LAC with amrA+B+-oprA+; amrAB-oprA expression under Ptac
b control [20]
pTNS3 Apr; source of Tn7 transposase components TnsABCD [20]
pFKM2 Apr Kmr; source of FRT-nptII-FRT cassette [20]
pFLPe2b Zeor; source of Flpe recombinase [20]
pPS1927 Apr; pWSK29 [47] with ,15 kb strain 1026b chromosomal EcoRI fragment containing amrA+B+-oprA+ This study
pPS2282 Apr; pGEM-T Easy (Novagen) with ,3.1 kb PCR fragment containing D(amrAB-OprA)::FRT-nptII-FRT t This Study
pPS2354 Gmr Kmr; pEX-S12pheS with ,3.1 kb blunt-ended EcoRI fragment of pPS2282 cloned into the SmaI site This Study
Primersc
597 59-CGAATTGGGGATCTTGAAGTTCCT This study
1546 59-TACATGGCGATAGCTAGACTGG This study
1599 59-CGCGCGCAATTGTTCCTC This study
1600 59-TCGTAAGAAAGCGACACGCA This study
1601 59-CGATTCTTCGCGCGTCTTG This study
1602 59-CGCGTGCGTGCCCATTCG This study
1742 59-AAGACCGCGCTCTATTACGA This study
1743 59-TCGTCACCGTATCAGTGCAT This study
1756 59-ATCTTGCCGTTGAAGTGTCC This study
1757 59-ATCGCTGAACACGAAGAACC This study
1774 59-ACTAGTAGTGAGCGCAACGCAATTA This study
1779 59-GCCTCTTCGCTATTACGC This study
1797 59-GTTCGTCGCCGAGGAGT This study
1801 59-GAAGCCGGTGAAATCGACG This study
1954 59-CTCAAGTCGGTGTCCATTCC This study
1955 59-ACGTTATCCGGCGTGATCT This study
2031 59-CCTGGTTCACCTGCTCGATG This study
2032 59-CTTCGTCGCTGCAAGAAACG This study
2033 59-CGATCGACCTGCCTGAAACC This study
2034 59-AGCTCGTCGTGAACACGGC This study
2035 59-GACGTAATGGAACGACGCGC This study
2036 59-CGTCGGCGCATTGAACGACA This study
2037 59-CGATTCGTACATCGCGGCGA This study
B. pseudomallei Aminoglycoside Susceptibility
www.plosntds.org 3 September 2009 | Volume 3 | Issue 9 | e0000519
ing ,40 kb inserts were isolated using the CopyControl Fosmid
Library Production Kit following manufacturer’s instructions
(Epicentre, Madison, WI). Approximately 1,200 Cmr resistant
colonies were pooled in groups of 30 (designated pools A–Z and
1–11), grown overnight in Cm containing medium, induced to
high copy number and fosmid DNA was extracted using the
QIAprep Mini-spin kit (Qiagen). Fosmid DNA from the 30 pools
were screened by PCR using primers 1742 and 1743, and PCR
products were obtained from 5 pools. DNA from these pools was
transformed into E. coli DH5a and single colonies were screened
for the presence of the correct clones by PCR using primers 1742
and 1743. DNA was extracted from these clones and sequenced
with primers 1774 and 1779 which anneal in the fosmid backbone,
as well as 1742 which anneals in the insert. Sequences obtained
with primers 1774 and 1779 were BLAST searched against
genome sequences of B. pseudomallei strains K96243, 1710b, 1106a
and 668.
Next Gen Sequencing and data analysis
The genome of strain 708a was sequenced using a short ‘‘read’’
technology to detect missing genes relative to reference genomes.
Five mg of DNA from B. pseudomallei strain 708a was sheared into
approximately 175 bp fragments using air nebulization. A
genomic library was then constructed following standard protocols
from Illumina, Inc. (San Diego, CA). The library was sequenced
on an Illumina Genome Analyzer (GA) using a single read
sequencing method. Image analysis for base calling and alignments
followed protocols of Craig et al. [25]. Genomic sequencing data
(42 bp reads) for strain 708a were aligned against the K96243 and
MSHR668 (data not presented) reference genomes using the
Illumina GA software. The aligned reads were then visualized
using the software program SolScape (Beckstrom-Sternberg et al.,
manuscript in preparation). Genomic regions with no reads were
interpreted as missing from the sequenced genome.
Isolation of gentamicin resistant mutants
Gentamicin resistant derivatives of strains 2188a and 3799a
were isolated in several steps. First, the strains were grown
overnight at 37uC in LSLB medium containing 8 mg/ml Gm. The
bacteria were then diluted into fresh LSLB medium containing
16 mg/ml Gm, followed by outgrowth at 37uC. The selection steps
were repeated using LSLB medium containing 32, 64 and
128 mg/ml Gm. Similar selection steps were performed with
708a except that lower Gm concentrations of 2, 4, 8 and 16 mg/ml
were employed.
Antimicrobial susceptibility testing
Minimal inhibitory concentrations (MICs) were determined in
Mueller-Hinton broth from Becton Dickinson (Franklin Lakes, NJ)
by the two-fold broth microdilution technique following Clinical
and Laboratory Standards Institute guidelines [26]. The MICs
were recorded after incubation at 37uC for 15 to 16 h.
Animal infection experiments
Ethics Statement: All animal procedures were performed using
standard protocols and according to guidelines approved by the
Colorado State University BioSafety Committee and the Colorado
State University Animal Care and Use Committee. For animal
infection experiments, B. pseudomallei strains were grown in LB
medium to saturation by overnight incubation at 37uC with
aeration. Glycerol was added to a final concentration of 15% and
cell suspensions were stored at 280uC until ready for use. Inocula
for in vivo infections were prepared by thawing and diluting the
frozen bacterial stocks in sterile phosphate buffered saline (Sigma-
Aldrich). Female BALB/c mice between 6–8 weeks of age were
used for infection studies (Jackson Laboratories, Bar Harbor, ME).
Mice were housed under pathogen-free conditions, and provided
sterile water and food ad libitum. All animal infections were done
using intranasal (i.n.) inoculation. Mice were anesthetized by
intraperitoneal injection of 100 mg/g body weight of ketamine (Fort
Dodge Animal Health, Overland Park, KS) and 10 mg/g body
weight of xylazine (Ben Venue Laboratories, Bedord, OH). For all
infections, the desired inoculum of B. pseudomallei was suspended in
phosphate buffered saline. The 20 ml inoculum volume was
delivered i.n, with the dose split evenly between both nostrils. At
the completion of challenge studies, animals were humanely
euthanized, according to study endpoints approved by the Animal
Care and Use Committee at Colorado State University.
Results and Discussion
Aminoglycoside and macrolide susceptible isolates show
reduced or absent AmrAB-OprA expression
In agreement with previously published results, the aminogly-
coside and macrolide susceptibility patterns of strains 708a, 2188a
and 3799a isolated from human patients with various disease
manifestations and clinical outcome (Table 2) were similar to
those observed with the AmrAB-OprA deficient strain DD503
(Table 3). Quantitative real-time PCR was therefore used to
assess amrAB-oprA expression relative to strain 1026b, which is
known to constitutively express this efflux pump. No amrB
transcripts were detected in strains 708a and D(amrAB-oprA) strain
DD503, and amrB transcript levels were significantly lower in
2188a and 3799a than those measured in 1026b (Fig. 1). As in our
hands 2 to 3 fold differences in mRNA levels determined by qRT-
PCR make the difference between low- and high-level RND
pump-mediated resistance, these data support the notion that the
aminoglycoside and macrolide susceptibilities of strains 708a,
2188a and 3799a are due to reduced or lack of AmrAB-OprA
efflux pump expression.
Gentamicin resistant derivatives of 2188a and 3799a, but
not 708a, express AmrAB-OprA
As we were able to PCR amplify the 59 and 39 regions of the
amrAB-oprA operon from strains 2188a and 3799a, but not 708a
Strain or Plasmid Relevant Propertiesa Reference or Source
2038 59-CTCAACTTCACGGGCGAGAT This study
aAbbreviations: AG, aminoglycosides; Ap, ampicillin; Gm, gentamicin; Km, kanamycin; ML, macrolides; r, resistance; Zeo, zeocin.
bPtac, E. coli lac/trp operon hybrid promoter.
cOnly selected primers are shown; other primer sequences are available from the authors upon request. Oligonucleotides were purchased from IDT, Coralville, IA.
doi:10.1371/journal.pntd.0000519.t001
Table 1. Cont.
B. pseudomallei Aminoglycoside Susceptibility
www.plosntds.org 4 September 2009 | Volume 3 | Issue 9 | e0000519
(data not shown), we suspected that this operon was absent from
708a and present but expressed at low levels 2188a and 3799a. To
test this notion, we attempted to isolate Gm resistant derivatives of
these strains. Highly (MIC.1024 mg/ml) Gmr derivatives, e.g.
Bp35 and Bp24, were readily obtained with strains 2188a and
3799a, but not with 708a (e.g. Bp66) (Table 3). Moreover, the
Gmr 2188a and 3799a derivatives Bp35 and Bp24 became
simultaneously resistant to other aminoglycosides and macrolides
and their antibiotic susceptibility profiles resembled that of
AmrAB-OprA expressing strain 1026b (Table 3). In contrast,
the moderately (MIC 32 mg/ml) Gmr derivative of 708a (Bp66)
did not simultaneously become resistant to other aminoglycosides
and erythromycin. None of the strains tested exhibited altered
clindamycin resistance. Clindamycin is a good substrate of BpeAB-
OprB but not AmrAB-OprA (T. Mima and H. Schweizer,
unpublished data). Consistent with these observations, significantly
increased amrB transcript levels were detected in Bp24 and Bp35
(Fig. 1, panels A and B), but not Bp66 (not shown). Deletion of
amrAB-oprA from Bp24 and Bp35 resulted in loss of aminoglycoside
and macrolide resistance which could be complemented back to
wild-type levels by a chromosomally integrated mini-Tn7
expressing amrA+B+-oprA+ (Table 3). Together, these results
indicate that the amrAB-oprA operon is absent from 708a and
present, but not expressed in sufficient levels in strains 2188a and
3799a to confer aminoglycoside and macrolide resistance.
Lack of AmrAB-OprA expression in 2188a and 3799a is
not due to mutations in the amrAB-oprA regulatory
region
To assess whether lack of amrAB-oprA expression in strains 2188a
and 3799a is due to mutations in the operon’s regulatory region, the
amrR-amrA intergenic region was amplified with primers 1601 and
1602 and sequenced. These analyses revealed that the sequence of
the amrR-amrA intergenic regions of strains 2188a and 3799a and
their Gmr derivatives Bp35 and Bp24 were identical (data not
shown). Furthermore, amplification of the amrR coding sequences
from 2188a and 3799a and their Gmr derivatives Bp35 and Bp24
with primers 1599 and 1600 did not reveal any mutations in amrR.
In summary, these data revealed that i) lack of AmrAB-OprA
expression in 2188a and 3799a was not caused by mutations in the
Table 3. Antibiotic susceptibilities of B. pseudomallei strains.
Strain Known Genotype
MIC (mg/ml) for:
Gma Str Spc Ery Cla Cli
1026b Wild-type 256 1024 512 128 64 .1024
DD503 1026b with D(amrR-amrAB-oprA) 2 NDb 64 8 4 .1024
708a 1 8 32 16 16 .1024
2188a 1 8 32 16 32 .1024
3799a 2 8 64 16 16 .1024
Bp24 Gmr derivative of 3799a .1024 1024 256 64 16 .1024
Bp35 Gmr derivative of 2188a .1024 .1024 .1024 256 512 .1024
Bp66 Low level Gmr derivative of 708a 32 8 16 4 16 .1024
Bp187 Bp24 with D(amrR-amrAB-oprA) 2 16 128 16 16 .1024
Bp202 Bp187::mini-Tn7T-LACc 4 32 128 8 16 .1024
Bp194 Bp187::mini-Tn7T-LAC-amrA+B+-oprA+c .1024 .1024 .1024 256 512 .1024
Bp192 Bp35 with D(amrR-amrAB-oprA) 2 16 128 16 16 .1024
Bp201 Bp192::mini-Tn7T-LACc 4 32 128 8 16 .1024
Bp200 Bp192::mini-Tn7T-LAC-amrA+B+-oprA+c .1024 .1024 .1024 256 256 .1024
aCla, clarithromycin; Cli, clindamycin; Ery, erythromycin; Gm, gentamicin; Spc, spectinomycin; Str, streptomycin.
bND, not done; DD503 is streptomycin resistant because of a chromosomal rpsL mutation.
cThe mini-Tn7 elements are integrated at the glmS2-associated Tn7 attachment site [20]. MIC values were determined in cells grown in the presence of 1 mM isopropyl-
b-D-thiogalactopyranoside.
doi:10.1371/journal.pntd.0000519.t003
Table 2. B. pseudomallei strains: origins, properties and clinical details.
Strain Isolation Date Clinical Details Gentamicin MICa
708a 30.8.90 32 year old male; 21 days fever and 14 days abdominal pain. No risk factors for melioidosis. Splenic abscess as
single infectious site. Splenectomy required to control infection. Treated with intravenous ceftazidime followed
by oral doxycycline. Survived.
0.5 mg/ml
2188a 18.12.98 22 year old male rice farmer; 14 days fever, cough, sputum, swollen left knee. Known diabetic. Bacteremic with
lung and joint involvement. Treated with joint washout and intravenous amoxicillin/clavulanic acid. Developed
respiratory failure and died the day after admission.
0.5 mg/ml
3799a 12.12.05 66 year old female rice farmer; 15 days cough, breathlessness, sputum. History of chronic renal failure. Bacteremic
with lung and renal involvement. Treated with ceftazidime. Died from septic shock 4 days after admission.
1 mg/ml
aMIC determinations were performed in Thailand using the E-test.
doi:10.1371/journal.pntd.0000519.t002
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amrAB-oprA regulatory region and ii) increased amrAB-oprA expres-
sion in Gmr derivatives Bp24 and Bp35 was not due to promoter-up
mutations or other amrR mutations. Rather, the data suggest that
AmrAB-OprA expression is governed by a yet unidentified
transcription factor or other positive regulatory mechanism(s). It is
well known that efflux pump operon expression in other bacteria is
governed by local as well as global mechanisms (reviewed in [27]).
For instance, mexAB-oprM operon expression in P. aeruginosa is under
control of the local MexR repressor [28], as well as other
mechanisms including the ArmR anti-repressor encoded by a gene
elsewhere on the chromosome [29].
Strain 708a contains a large deletion on chromosome 1
Results of PCR and qRT-PCR analysis were consistent with the
notion that the amrAB-oprA operon was missing from strain 708a.
Using the 1710b chromosome 1 sequence as a guide, primer sets
were designed to amplify ,500 bp fragments in the amrAB-oprA
containing region of chromosome 1. Results of this primer walking
strategy identified a correct PCR product obtained with primer set
1742 and 1743 designed to amplify sequences located ,5 kb
upstream of amrR. However, no PCR products were obtained with
primers designed to sequences located up to 65 kb downstream of
oprA. These data were consistent with the presence of a large
(.70 kb) deletion on chromosome 1 encompassing amrAB-oprA. To
determine the deletion boundaries, a fosmid library was constructed
using 708a chromosomal DNA. By PCR amplification, several
fosmids containing DNA previously located,5 kb upstream of amrR
were identified. Sequence analyses of both fosmid-chromosomal
DNA boundaries and BLAST analyses using four B. pseudomallei
genomes revealed the same open reading frames (ORFs) at the
respective junctions, BURPPS1710b_2037 (or its respective homo-
log in other genomes) and BURPPS1710b_2160 (or its respective
homolog in other genomes). A series of primers was designed to
determine the sequence adjacent to the primer 1742 binding site.
The sequence was aligned to that of 1710b and revealed a fusion of
ORFs BURPPS1710b_2155 and BURPPS1710b_2054. We inter-
preted this to mean that compared to 1710b, the 708a sequence was
missing nucleotides 2,219,259–2,359,936 (or ,141 kb) from
chromosome 1, including amrAB-oprA.
When compared to other strains, the extent of the deletion varied
by approximately 610 kb based on sequence from strains used as
comparators. For example, when compared to K96243 the deletion
is,131 kb (Fig. 2). The deletion was further confirmed by: i) PCR
amplification using primers 1797 and 1801 and DNA sequence
analysis of a 1.1 kb chromosomal DNA fragment from 708a
genomic DNA containing the predicted deletion junction; and ii)
short read whole genome sequencing of the 708a genome (Fig. 3).
Genes contained within the large deletion present in
708a chromosome 1
Because of the more thorough and detailed annotation of the
published K96243 genome we decided to use it to assess key genes
missing from B. pseudomallei strain 708a. According to K96243
coordinates, 708a is missing nucleotides 2,024,622 to 2,155,357
fusing the BURPPS1710b_2155 and BURPPS1710b_2054 equiva-
lents BPSL1717 and BPSL1807 (Fig. 2). In K96243, as well as 1710b
and other B. pseudomallei strains, this .90 gene region not only
contains amrAB-oprA but several other genes that may be pertinent to
this bacterium’s physiology and pathogenesis (Table 4). First, this
deleted region contains the 13 gene malleobactin biosynthetic gene
Figure 2. Extent of chromosome 1 deletion in strain 708a compared to K96243. 708a contains a deletion fusing the bold sequences of
BPSL1717 and BPSL1807, respectively. Some notable genes and gene clusters present in K96243 but missing from 708a are: 1 amrR-amrAB-oprA; 2 a
three gene operon (BPSL1801-BPSL1800-BPSL1799) encoding a putative type-1 fimbrial protein along with its outer membrane usher protein and
chaperone; 3 the 13 gene malleobactin biosynthetic gene cluster and its extracytoplasmic sigma factor MbaS defined by mbaF-fmtA-mbaA-mbaI-
mbaJ-mbaE-BPSL1781-BPSL1782-BPSL1783-BPSL1784-BPSL1785-BPSL1786-mbaS; 4 a cluster of 18 genes (BPSL1755-BPSL1773) encoding a putative
aerobic (or late cobalt insertion) vitamin B12 biosynthetic pathway with an embedded gene (BPSL1763) encoding a putative exported chitinase; 5
arcD (BPSL1742) and arcABC (BPSL1743-BPSL1744-BPSL1745) coding for the arginine deiminase pathway; and 6 a two gene cluster (BPSL1732-
BPSL1731) coding for a putative methyl-accepting chemotaxis citrate transducer and chemotaxis protein CheW2, respectively. Strain 1710b contains
an additional 10 kb of DNA in this region.
doi:10.1371/journal.pntd.0000519.g002
Figure 1. amrB transcript levels in gentamicin susceptible and
resistant strains. mRNA levels in LSLB without antibiotics-grown late-
log cultures of the indicated strains were determined with an amrB-
specific primer set. Data were normalized using the 23S rRNA gene as
the housekeeping control. amrB transcript levels were determined A in
strain 2188a and its gentamicin resistant derivative Bp35 and B in strain
3799a and its gentamicin resistant derivative Bp24. Relative quantifi-
cations were performed using 2188a and 3799a, respectively.
doi:10.1371/journal.pntd.0000519.g001
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cluster and its extracytoplasmic sigma factor MbaS defined by
mbaF-fmtA-mbaA-mbaI-mbaJ-mbaE-BPSL1781-BPSL1782-BPSL1783-
BPSL1784-BPSL1785-BPSL1786-mbaS [30]. Malleobactin is a
hydroxamate siderophore that is analogous to the same genes in
Pseudomonas aeruginosa pyoverdine [31] and B. cepacia ornibactin [32].
Pyoverdine is essential for infection and full virulence of P. aeruginosa,
as assessed in several different experimental models [33], along with
biofilm formation [34]. Similarly, B. cepacia mutants defective in
ornibactin synthesis showed significantly reduced virulence [32].
However, in the case of 708a, despite missing the entire malleobactin
biosynthetic gene cluster and exhibiting overall greatly reduced
siderophore synthesis (as assessed by growth on Chrome azurol S
plates) [30,35] (data not shown), the 708a stain was still able to cause
severe illness in the infected human from which it was isolated
(Table 2). Moreover, strain 708a was also fully virulent in our acute
inhalational challenge model in mice (Fig. 4). Thus, it is possible that
malleobactin may not play the same crucial role in infection and
virulence that the P. aeruginosa pyoverdine siderophore does.
Alternatively, B. pseudomallei is known to synthesize other iron
transport systems, including a pyochelin siderophore and heme-
hemin receptor and transporter [30,36], and thus 708a may utilize
these alternative pathways for iron transport. Second, immediately
adjacent to the malleobactin biosynthetic genes is a cluster of 18
genes (BPSL1755-BPSL1773) encoding a putative aerobic (or late
cobalt insertion) vitamin B12 biosynthetic pathway [37]. Vitamin B12
is a known cofactor for numerous enzymes mediating methylation,
reduction and intramolecular rearrangements. Why this pathway is
dispensable for growth in 708a is not known. However, some
bacteria are known to possess an alternative anaerobic (or early
cobalt insertion) pathway [37]. Third, the deletion in 708a
encompasses the genes arcD (BPSL1742) and arcABC (BPSL1743-
BPSL1745) coding for the arginine deiminase pathway. In P.
aeruginosa, this pathway provides for ATP synthesis under anaerobic
conditions in the absence of exogenous electron acceptors provided
that arginine is present in the growth medium [38]. In this context it
is worthy of note that 708a was isolated from a splenic abscess and
abscesses are generally considered to provide a mixed aerobic-
anaerobic environment [39,40]. If 708a was truly able to grow under
anaerobic conditions, then 708a must be capable of utilizing
alternative pathways for energy generation under anaerobic
conditions. This alternate pathway presumably would require
nitrate as B. pseudomallei was shown to be capable of growing
anaerobically only in the presence of arginine and nitrate [41].
Fourth, other noteworthy genes covered by the deletion include
i) a three gene operon (BPSL1801-BPSL1799) encoding a putative
type-1 fimbrial protein along with its outer membrane usher
protein and chaperone; ii) a two gene cluster (BPSL1732-
BPSL1731) coding for a putative methyl-accepting chemotaxis
citrate transducer and chemotaxis protein CheW2, respectively;
and iii) a putative exported chitinase (BPSL1763).
Genes missing from the 131 kb deletion are not present
elsewhere on the chromosome
To assess whether the aforementioned genes were indeed absent
from the chromosome we performed i) whole genome sequencing
and ii) PCR analysis of selected genes.
Genomic alignments were performed to compare 708a data
with two B. pseudomallei reference genomes: strains K96243 and
MSHR668. The 42 bp reads had an average density of 246 and
covered 93.3% (chromosome 1) and 96.9% (chromosome 2) of the
reference genomes. The notable exception to this coverage was a
,130.7 Kb region corresponding to positions 2,024,621 and
2,155,359 in chromosome 1 of the K96243 genome (Fig. 3).
Nearly zero reads aligned to this region indicating that the 708a
strain does not contain any of these genes. While these data do not
discern gene order or chromosomal linearity between 708a and
the reference genomes, this does represent a comprehensive query
and argues that the genes in this region are not present anywhere
in the 708a genome. If homologous genes existed elsewhere in the
708a genome, they would have generated short reads that would
have aligned with this region. The short read data are available
online at http://www.mggen.nau.edu/MGGen_research.html.
Because whole genome sequence coverage was not 100% for
both chromosomes, we performed PCR analysis for selected genes
using gene-specific primers designed for amplification of the
corresponding K96243 sequences (Fig. 5). PCR analysis showed
the expected DNA fragments with genomic DNA templates from
K96243 but not with 708a templates. The identities of the
amplified DNA fragments were verified by DNA sequence
analyses which also confirmed minor bands visible in some PCR
reactions from 708a templates as non-specific amplification
products. As a positive control, we amplified a fragment from
the BPSL1809-BPSL1810 region using primers 1742 and 1743.
This region is present in both 708a and K96243. The 445 bp
amplicon derived from K96243 DNA consists of 243 bp from
BPSL1810 and 202 bp from the BPSL1809-BPSL1810 intergenic
region. The corresponding fragment obtained with 708a DNA is
slightly larger (479 bp) because of several insertions in the
BPSL1809-BPSL1810 intergenic region.
Figure 3. Large deletion verification in chromosome 1 of strain 708a by whole genome sequencing. Genomic sequencing data from
strain 708a were aligned against the K96243 reference genome. Panel A shows the read density near positions 2,024,621 and 2,155,359 on
chromosome 1. Panel B shows the 708a read density across the ,4.5 Kb flanking the deletion in chromosome 1 of strain K96243. The yellow
highlighted region in panel B marks a ,130.7 Kb region with a near-zero read coverage, which correspond to the panel A coordinates. This lack of
reads is strong evidence for deletion of the entire region in strain 708a.
doi:10.1371/journal.pntd.0000519.g003
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Table 4. K96243 gene equivalents contained within the 708a
chromosome 1 deletion.
Locus Tag or Gene Putative or Known Function
BPSL1717 Hypothetical protein
BPSL1718 Hypothetical protein
BPSL1719 Putative kinase
BPSL1720 Putative argininosuccinate lyase
BPSL1721 Putative argininosuccinate synthase
BPSL1722 Putative formyl transferase
BPSL1723 Hypothetical protein
BPSL1724 Putative histidinol-phosphate aminotransferase
BPSL1725 Hypothetical protein
BPSL1726 Hypothetical protein
BPSL1727 Putative non-ribosomal peptide synthase (thioesterase
domain)
BPSL1727 Putative non-ribosomal peptide synthase (thioesterase
domain)
BPSL1728 Putative exported porin
BPSL1729 Putative AraC-family transcriptional regulator
BPSL1730 Putative transmembrane protein
BPSL1731 Chemotaxis protein CheW2
BPSL1732 Putative methyl-accepting chemotaxis citrate
transducer
BPSL1733 Hypothetical protein
BPSL1734 Acyl-CoA synthase
BPSL1735 Putative transport system membrane protein
BPSL1736 Putative methyltransferase
BPSL1737 Putative ABC transport system, exported protein
BPSL1738 Putative ABC transport system, membrane protein
BPSL1739 Putative ABC transport system, ATP-binding protein
BPSL1740 Putative ABC transport system, membrane protein
BPSL1741 Hypothetical protein
arcD Arginine/ornithine antiporter
arcA Arginine deiminase
arcB Ornithine carbamoyltransferase
arcC Carbamate kinase
BPSL1746 Short chain dehydrogenase
BPSL1747 Hypothetical protein
BPSL1748 Putative LysR-family transcriptional regulator
BPSL1749 Putative glutathione S-transferase
BPSL1750 Putative MarR-family transcriptional regulator
BPSL1751 Putative amino-acid transport-related exported protein
BPSL1752 Putative MarR-family regulatory protein
BPSL1753 Putative transport-related membrane protein
BPSL1754 Putative lipoprotein
BPSL1755 Precorrin-4 C11-methyltransferase
BPSL1756 Precorrin-66 reductase
BPSL1757 Cobalt-precorrin-6A synthase
BPSL1758 Precorrin-6Y C5,15-methyltransferase
BPSL1759 Putative oxidoreductase
BPSL1760 Precorrin-86methylmutase
BPSL1761 Precorrin-2 methyltransferase
BPSL1762 Precorrin-3b C17-methyltransferase
Locus Tag or Gene Putative or Known Function
BPSL1763 Putative exported chitinase
BPSL1764 Hypothetical protein
BPSL1765 Putative carboxylesterase
BPSL1766 Hypothetical protein
BPSL1767 Putative magnesium chelatase protein
BPSL1768 Cobaltochelatase
BPSL1769 Putative cobalamin biosynthesis-related protein
BPSL1770 High-affinity nickel transport protein
BPSL1771 Cobalamin biosynthesis protein CbiG
BPSL1772 Cob(I)yrinic acid a,c-diamide adenosyltransferase
BPSL1773 Cobyrinic acid A,C-diamide synthase
mbaF Putative N5-hydroxyornithine transformylase1
fmtA Malleobactin receptor
mbaA Putative L-ornithine-N5-oxygenase
mbaI Putative non-ribosomal peptide synthase
mbaJ Putative non-ribosomal peptide synthase
mbaE Similar to P. aeruginosa pvdE (ABC transporter)
BPSL1780 Hypothetical protein
BPSL1781 Putative periplasmic iron-binding protein
BPSL1782 Putative ferric iron reductase
BPSL1783 Putative iron transport-related membrane protein
BPSL1784 Putative iron transport-related ATP-binding protein
BPSL1785 Hypothetical protein (similar to syrP from Streptomyces
verticillus)
BPSL1786 Hypothetical protein (similar to mbtH from
Mycobacterium tuberculosis)
mbaS MbaS, extracytoplasmic sigma factor
BPSL1788 Pseudogene
BPSL1789 Short chain dehydrogenase
BPSL1790 Putative zinc-binding dehydrogenase
BPSL1791 Hypothetical protein
BPSL1792 Hypothetical protein
BPSL1793 Putative sugar-binding exported protein
BPSL1794 Putative AraC-family transcriptional regulator
BPSL1795 Hypothetical protein
BPSL1796 Hypothetical protein
BPSL1797 Putative ABC transport system, membrane protein
BPSL1798 Hypothetical protein
BPSL1799 Putative fimbrial chaperone
BPSL1800 Putative outer membrane usher protein precursor
BPSL1801 Putative type-1 fimbrial protein
BPSL1802 OprA multidrug efflux outer membrane channel protein
BPSL1803 AmrB multidrug efflux system transporter protein
BPSL1804 AmrA multidrug efflux system membrane fusion
protein
BPSL1805 AmrR TetR family regulatory protein
BPSL1806 Subfamily M23B unassigned peptidase
BPSL1807 Putative amino acid transport system, membrane
protein
1Annotation of BPSL1774 (mbaF) through BPSL1787 (mbaS) according to Alice
et al. [30].
doi:10.1371/journal.pntd.0000519.t004
Table 4. Cont.
B. pseudomallei Aminoglycoside Susceptibility
www.plosntds.org 8 September 2009 | Volume 3 | Issue 9 | e0000519
In summary, these findings provide some insight into the
physiology and pathogenesis of B. pseudomallei. However, because
708a grows normally in rich and minimal laboratory media under
aerobic conditions, is fully virulent in an acute murine melioidosis
model and caused human melioidosis, the genes affected by the
deletion must be dispensable at least under the in vitro and in vivo
conditions encountered during laboratory studies and splenic
abscess disease during human infection caused by lone presence of
708a. This scenario is likely as simultaneous infection with more
than one strain is uncommon in human melioidosis [42].
Concluding remarks
The clinical diagnosis of Burkholderia pseudomallei still relies on
culture which is most commonly performed using selective Ash-
down’s agar whose main selective ingredient is gentamicin. The
majority of B. pseudomallei strains grow on this medium because of
their intrinsic resistance to aminoglycosides mediated by the
AmrAB-OprA efflux pump. At least 1 in 1,000 clinical isolates in
NEThailand are susceptible to aminoglycosides and such isolates are
obviously missed by using Ashdown’s diagnostic agar. The actual
number of aminoglycoside susceptible strains may thus be higher.
Our results confirm that the aminoglycoside and macrolide
susceptibility of rare clinical isolates is indeed due to reduced or
lack of expression of the amrAB-oprA efflux pump operon, as
previously suggested but not proven [16]. Even though BpeAB-
OprB was previously implicated to contribute to aminoglycoside and
macrolide resistance in strain KHW [14], we now know that this
pump does not confer aminoglycoside resistance in 1026b (T. Mima
and H. Schweizer, unpublished observations), a strain isolated in the
same hospital as 708a. BpeAB-OprB is only expressed at very low
levels in wild-type strains which may explain the low levels of
erythromycin resistance observed in 708a, 2188a and 3799a in the
absence of AmrAB-OprB. This notion is supported by the
observation that all strains analyzed in this study exhibit clindamycin
resistance. Clindamycin is a good substrate of BpeAB-OprB but not
AmrAB-OprA (T. Mima and H. Schweizer, unpublished data). As
expected, qRT-PCR analyses showed only low-level BpeAB-OprB
expression in these strains (data not shown). Though strain 708a
contains a large deletion encompassing several gene clusters
encoding potential virulence factors and genes required for growth
under anaerobic conditions, these genes may either be dispensable
for in vitro and in vivo growth or this strain compensates for them by
expressing similar functions from another set of genes. The latter
notion may be supported by the observation that the genetically
engineered 1026b AmrAB-OprA mutant derivative Bp50 shows
reduced virulence in the murine melioidosis model whereas 708a
missing these genes is as virulent as 1026b (Fig. 4). We do not know
the factors, if any, that led to selection of strains missing or lacking
expression of AmrAB-OprA. Further experiments aimed at
addressing some of these issues at the molecular level are facilitated
by availability of the nearly complete 708a sequence and tools that
allow genetic manipulation of this strain. Lastly, because 708a is fully
virulent in the murine melioidosis model, yet very susceptible to
aminoglycosides, this strain may be a natural candidate for genetic
manipulation experiments that use Select Agent compliant antibi-
otics for selection, such as gentamicin [20], kanamycin [20],
spectinomycin/streptomycin [43] and nourseothricin [44] selection
markers, and validates the use of laboratory-constructed D(amrAB-
oprA) mutants in such experiments [13,20].
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